YUPELRI®
revefenacin inhalation solution

For use with any standard jet nebulizer with a mouthpiece



Indication

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta$_2$-agonist.

See other side for additional Important Safety Information.

YUPELRI®
revefenacin inhalation solution

The **first and only** once-daily nebulized long-acting muscarinic antagonist (LAMA)

Product Name: YUPELRI (revefenacin)

NDC: 49502-806-93

Dosage Form: Inhalation Solution

Shelf Life: 24 months

Pack Size: 1 carton contains 30 unit-dose vials

Strength: 175 mcg/3 mL

Storage and Handling: Store at room temperature from 68°F to 77°F (20°C to 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C). Protect from direct sunlight and excessive heat.

Wholesaler	Item Number
AmerisourceBergen Drug Corporation	10192927
Anda	602315
Capital Wholesale Drug & Co.	280693
Cardinal Health	5498050
Dakota Drug, Inc.	28878
DMS Pharmaceutical Group	811480
H. D. Smith	5777750
McKesson Corporation	3567104
Morris & Dickson Company, LTD.	496786
North Carolina Mutual Wholesale Drug	329680
PBA Health	4950280693
Prescription Supply Inc.	960708
R&S Northeast	80693
Rochester Drug Cooperative Inc.	10783074
Smith Drug Company	871376
Valley Wholesale Drug	697920
Value Drug Company	222011

Indication

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta$_2$-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

Please see accompanying Full Prescribing Information.

For more information or to order products, please contact Mylan Customer Relations at 1.800.796.9526

Mylan®

Theravance Biopharma

REV-2019-0211